Welcome to our dedicated page for Numinus Wellness news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on Numinus Wellness stock.
Numinus Wellness Inc. reports developments in mental health care, clinical research operations, and practitioner training tied to regulated botanical wellness-assisted therapies. The company’s updates describe Cedar Clinical Research, Numinus Practitioner Training, clinical trial site readiness, therapist education, protocols, reimbursement infrastructure, and care models for depression, anxiety, trauma, pain, and substance use.
Recurring news also covers quarterly financial results, auditor changes, exchange-listing status, cease-trade-order remediation efforts, and regulatory developments affecting botanical wellness compounds such as ibogaine, MDMA, and LSD.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced participation in a Water Tower Research Fireside Chat on April 19, 2023, at 11:30 a.m. ET. The event will feature CEO Payton Nyquvest discussing key insights from the company’s fiscal Q2 2023 results, sector developments, and upcoming catalysts. Interested individuals can register here. Numinus focuses on innovative mental healthcare and psychedelic-assisted therapies aimed at treating mental health issues, establishing a foundation for a healthier society.